Substrate-based kinase activity inference identifies MK2 as driver of colitis

Area of Science:

• Molecular biology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) lacks effective treatments due to incomplete understanding of its molecular basis.
• Protein phosphorylation plays a crucial role in cellular signaling, but its function in IBD is not fully elucidated.

Purpose of the Study:

• To develop a novel computational method for inferring kinase activity from phosphoproteomic data.
• To identify key kinases involved in IBD pathogenesis using this new method.
• To evaluate a potential therapeutic strategy targeting identified kinases in IBD models.

Main Methods:

• Developed Substrate-based Kinase Activity Inference (SKAI) using prior knowledge of kinase-substrate interactions.
• Applied SKAI to phosphoproteomic data from two mouse models of IBD.
• Utilized Gene Set Enrichment Analysis to infer kinase activity from substrate phosphorylation changes.
• Administered the MK2 inhibitor ATI450 to mice with active colitis.

Main Results:

• SKAI successfully inferred kinase activity profiles from phosphoproteomic data.
• SKAI identified largely distinct kinase activation patterns in the two IBD models.
• Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2) was the only kinase consistently activated in both models.
• ATI450 treatment reduced inflammatory signaling and ameliorated IBD symptoms in mice.

Conclusions:

• MK2 is a critical therapeutic target for inflammatory bowel disease.
• The SKAI methodology provides a powerful tool for analyzing phosphoproteomic data to uncover signaling pathways.
• ATI450 represents a promising therapeutic candidate for IBD treatment.